The unanticipated increased use of propofol as a sedative for ventilated patients has strained the nation’s propofol supply for intensive care units. As a result, the FDA has issued an Emergency Use Authorization (EUA) for emergency use of the Fresenius Kabi Propoven 2% Emulsion to maintain sedation via continuous infusion in patients 16 years and older who require mechanical ventilation in an intensive care unit (ICU) during the COVID-19 pandemic.
|
